City Therapeutics

NEWS

Illustration showing candidate resume being reviewed by employer

Job Trends

Ones to watch: 4 biotechs with recent Series B raises (that are also hiring)

Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.

June 18, 2026

4 min read

Angela Gabriel

A city with electric wires and pipes underground.

Series B

City Therapeutics builds RNAi pipeline with $99.5M series B

City Therapeutics, one of BioSpace’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.

June 8, 2026

2 min read

Tristan Manalac

Full 3d poster art collage of anonym people wear armor two soldiers stand america china flag battle confrontation trade war.

NextGen

Facing pressure from China, BioSpace’s NextGen biotech leaders say: ‘Bring it on’

From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night.

June 3, 2026

6 min read

Annalee Armstrong

NextGen

BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets

From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.

January 7, 2026

2 min read

Annalee Armstrong

IN THE PRESS

Press Releases

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

June 9, 2026

3 min read

Press Releases

City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting

May 6, 2026

2 min read